Company intelligence / Profile preview

MedDay Pharmaceuticals

Paris, Île-de-France, Francemedday-pharma.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

MedDay’s lead candidate MD1003—a high-dose biotin formulation—has completed pivotal Phase 2b/3 studies in progressive multiple sclerosis with proof-of-concept showing up to 90% of subjects exhibiting clinical improvement. Additional programs are at earlier stages targeting rare neurological and psychiatric diseases. The company leverages its proprietary SPECMET platform for drug discovery focused on brain metabolism.

Therapeutic areas: PsychiatryRare DiseasesNeurology
Modalities: small molecules (notably high-dose pharmaceutical-grade biotin)
Industry: Biotech

Drug pipeline

1 asset

MD1105

Preclinical

Partnerships

European Leukodystrophy Association funds the AMN trial; no major pharma partnerships disclosed

Beyond the preview

Go deeper on MedDay Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedDay Pharmaceuticals.

Explore the full profile